Empowering
people living with
rare immunologic diseases
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
Media
Our latest announcements
03/04/2025
25/03/2025
Regulatory press release
21/03/2025
11/03/2025
Autoimmune Deep Dive Guillain-Barré Syndrome
Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS), an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.
Monday, June 16, 2025 | 14:00 CEST / 8:00 AM ET
Live Webcast
Our focus area
We aim to address unmet need in conditions where the IgG-driven immune response becomes harmful, or it interferes with the delivery of lifesaving and life altering therapies.

For Investors
Upcoming events
Interim Report for January-March 2025
Annual General Meeting 2025
Autoimmune Deep Dive - Guillain-Barré Syndrome
Media articles
Discover more
Partner with us
Our partnership model is focused in three key areas – drug discovery and development, commercialization and distribution / licensing.
PartnershipsJoin us
Ready for a new career? Check out our job opportunities.
A truly great place to work
For five years Hansa has been awarded the Great Place To Work designation by the independent institute Great Place To Work®, a global authority on workplace culture, employee experience and leadership behavior.
Job opportunities